Accelerated Approvals & Value Models

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, particularly the FDA guidance piece.

MarcusSame here. We're looking at FDA's draft guidance on real-world data for accelerated approvals — what signals this sends for evidence generation. Then CMS's proposed changes to Medicare Advantage Star Ratings — how this reshapes provider incentives. And NICE's consultation on thresholds for highly specialized technologies — the £50k threshold question. Plus EMA's adaptive licensing initiative for rare diseases — a potential paradigm shift.

SaraThat CMS Star Ratings update is interesting to me — the budget impact implications could ripple through oncology and chronic care models if they prioritize PROs more heavily.

MarcusExactly. Let's get into it.

MarcusStarting with the FDA's draft guidance on real-world data for accelerated approvals. They're explicitly allowing RWE to support confirmatory trials post-accelerated approval. This could streamline evidence generation for drugs with surrogate endpoints, especially in oncology and neurology.

SaraThat's one read — I'd frame it slightly differently though. The guidance emphasizes data quality standards that are nearly as rigorous as pivotal trials. What strikes me is the increased burden on sponsors to design robust RWE studies that satisfy FDA's evidentiary bar. It's not a shortcut.

MarcusFair point. The guidance does stress prospective data collection and control groups. But it does recognize RWE can fill gaps when traditional trials are impractical. For drugs like Alzheimer's therapies where long-term outcomes take years, this could be game-changing.

SaraThe part that gives me pause is the liability framework. If RWE is used to confirm accelerated approvals, what happens if the confirmatory trial fails? Sponsors might face reputational and financial risks that could deter innovation in high-need areas. That's a tension worth watching.

MarcusThat connects to something I keep coming back to: the FDA is walking a tightrope here. They want to accelerate access for serious conditions but can't compromise on evidentiary standards. This guidance might actually push for earlier, more robust RWE planning in development programs.

SaraRight, and from the payer side, we'd need clearer signals on how CMS will integrate these RWE-based approvals into coverage decisions. If the evidence is strong enough for FDA, does it automatically meet our value thresholds? That's not yet defined.

MarcusExactly. Let's move to CMS and Medicare Advantage Star Ratings.

SaraCMS proposed changes to Medicare Advantage Star Ratings that would significantly weight patient-reported outcomes and social risk factors. This could fundamentally shift how providers measure success beyond just clinical metrics.

MarcusThat's a seismic shift. By giving PROs up to 20% weight in star ratings, CMS is essentially forcing providers to invest in patient experience and health-related quality of life. For innovative therapies, this could create new pathways to demonstrate value if they improve PROs.

SaraI wonder if that's the full picture though. The proposal also adds social risk factors like housing instability and food insecurity to risk adjustment. While well-intentioned, this could dilute the signal of clinical effectiveness. We might see providers prioritize addressing social determinants over delivering optimal care for complex conditions.

MarcusThat's a valid concern. But what's striking here is how this aligns with value-based care principles. If a therapy significantly improves PROs, providers now have a direct incentive to prescribe it. This could make cost-effectiveness arguments more compelling when PRO data is strong.

SaraThe budget impact question remains though. If providers are incentivized to prescribe therapies with high PRO impact but high costs, how does that affect Part D premiums? CMS hasn't fully modeled that yet. This could create tension between patient experience and system sustainability.

MarcusFair. But I'd push back slightly on that — the proposal also includes new measures for chronic care management. If therapies reduce hospitalizations and emergency visits, the net cost impact might be positive. It's a holistic view that could favor therapies with strong PROs and utilization reductions.

SaraThat's true, but the devil's in the implementation details. We'll need to see how CMS operationalizes these measures. If PROs are measured inconsistently across plans, it could create perverse incentives. This one bears watching closely as the comment period unfolds.

MarcusAgreed. Next, NICE's consultation on thresholds for highly specialized technologies.

MarcusNICE is consulting on raising the cost-effectiveness threshold for highly specialized technologies to £50,000 per QALY. This could be pivotal for ultra-orphan drugs and complex gene therapies that currently struggle to meet the £20k-30k threshold.

SaraThat's a significant jump. While I understand the need for ultra-rare disease treatments, raising thresholds to £50k could strain NHS budgets. The consultation also mentions a new 'exceptional circumstances' category, which might apply to technologies with no alternatives and high unmet need. But how will they define 'exceptional'? That's the key question.

MarcusThe methodology is evolving. NICE is proposing to incorporate broader value elements like caregiver burden and societal impact. For therapies that transform lives despite high costs, this could provide a more nuanced assessment. But I'm curious about the budget impact implications — if multiple ultra-orphan drugs qualify, how does that affect system-wide resources?

SaraThat's precisely what concerns me. The consultation doesn't address opportunity cost trade-offs explicitly. If one ultra-orphan drug gets a £50k threshold, what does that mean for other innovations? We need clearer parameters on how many such exceptions the system can sustain. Otherwise, it risks becoming politically unsustainable.

MarcusI see your point, but NICE is trying to balance innovation access with fiscal responsibility. The proposed 'value-based risk-sharing' arrangements could help — spreading payments over time based on outcomes. This might make ultra-orphan therapies more palatable for commissioners.

SaraRisk-sharing is a step forward, but it adds administrative complexity. And if multiple therapies use similar models, it could create a patchwork of agreements. I'd like to see more transparency on how NICE will prioritize which technologies qualify for the higher threshold. That's the missing piece in this consultation.

MarcusThat's fair. Finally, EMA's adaptive licensing initiative for rare diseases.

SaraEMA launched a new adaptive licensing framework for rare diseases that allows earlier conditional approvals based on preliminary efficacy data, with post-marketing requirements to confirm benefit. This could dramatically accelerate access for ultra-rare conditions with limited patient populations.

MarcusThis is a pragmatic evolution. By accepting smaller datasets and surrogate endpoints in initial approvals, EMA is acknowledging the realities of rare disease development. The framework requires robust post-marketing studies, but it could bring therapies to patients years earlier than traditional pathways.

SaraWhat strikes me is the potential divergence with HTA bodies. If EMA approves based on preliminary data, how will NICE or other agencies assess value? They might require more evidence, creating transatlantic access delays. The initiative doesn't address HTA alignment, which could be a hurdle for market access.

MarcusThat's a crucial point. The EMA is focused on regulatory approval, but HTA bodies operate on different value frameworks. We might see more conditional approvals with divergent reimbursement decisions. However, the initiative does encourage early engagement with HTA bodies, which could help bridge that gap.

SaraEarly engagement is good, but it doesn't guarantee alignment. Payers will still need robust evidence to justify reimbursement. For ultra-rare diseases with small populations, generating that evidence post-approval will be challenging. This could leave therapies approved but not reimbursed, which doesn't help patients.

MarcusI agree, but the alternative is no approval at all for many rare diseases. This framework at least creates a pathway. And with real-world data requirements, it might generate the evidence needed for HTA over time. It's not perfect, but it's a step forward for conditions with no options.

SaraThat's true. We'll need to see how it plays out in practice. The first adaptive licensing decisions will set precedents for how much preliminary evidence is acceptable. That will be telling for the field.

MarcusDefinitely. A lot to think about today. I'll be watching how CMS operationalizes the Star Ratings PRO weighting — that could redefine provider incentives for innovative therapies.

SaraSame — and for me the thread running through today is the tension between accelerating access and maintaining evidentiary standards. Each initiative pushes boundaries, but the implementation details will determine real-world impact.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.